XM does not provide services to residents of the United States of America.

Indian shares fall ahead of Fed rate decision



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Indian shares fall ahead of Fed rate decision</title></head><body>

Updates for morning trade

By Hritam Mukherjee

Dec 18 (Reuters) -Indian shares declined on Wednesday, extending losses from the previous session, as investors braced for the FederalReserve's final monetary policy decision for the year, which will be closely monitored forclues on its future rate-cut path.

The Nifty 50 .NSEI was down 0.5%at 24,211 points as of 11:10 a.m. IST, while the BSE Sensex .BSESN fell 0.54% to 80,244.

The indexes fell more than 1% on Tuesday, bogged down by foreign outflows, withthe Nifty 50 closing below its 50-day moving average.

Twelve of the 13 major sectoral indexes were trading lower on the day.The more domestically-focussed small .NIFSMCP100 and midcaps .NIFMDCP100 both were both down 0.4%.

"Investor caution, likely from foreigners, persists... with an eye out for how hawkish will the Fed be in 2025 in terms of rate reductions," said Ruchit Jain, head of technical research at Motilal Oswal Financial Services.

Foreign investors offloaded Indian stocks worth about 64.1 billion rupees ($755 million) on a net basis on Tuesday, exchange datashowed.

While aquarter-point ratecut from the Fed isnear-certain later in the day, investors are jittery about the central bank's rate outlook in 2025 due to sticky inflation in the United States and a relatively strong economy. Markets will keep a keen eye on anycautious commentary from the Fed.

U.S. rate cutstypically help emerging market assets, such as Indian equities, as they boost foreign inflows.

On the day, Nifty 50 heavyweights HDFC Bank HDBK.NS and ICICI Bank ICBK.NS dropped over 1% and were the biggest drags on the index.

Online payments firm MobiKwik ONEM.NS soared 80% and budget retailer Vishal Mega Mart VSSL.NS jumped 37% in their respective trading debuts.

TPG-backed drugmaker Sai Life Sciences SAIE.NS gained 28% in its market debut.


($1 = 84.9040 Indian rupees)




Reporting by Hritam Mukherjee in Bengaluru; Editing by Sherry Jacob-Phillips and Sonia Cheema

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.